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Abstract
Background: Angiogenesis, the growth of new blood vessels from the pre-existing vasculature is
associated with physiological (for example wound healing) and pathological conditions (tumour
development). Vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2) and
epidermal growth factor (EGF) are the major angiogenic regulators. We have identified a natural
product (cheiradone) isolated from a Euphorbia species which inhibited in vivo and in vitro VEGF-
stimulated angiogenesis but had no effect on FGF-2 or EGF activity. Two primary cultures, bovine
aortic and human dermal endothelial cells were used in in vitro (proliferation, wound healing,
invasion in Matrigel and tube formation) and in vivo (the chick chorioallantoic membrane) models
of angiogenesis in the presence of growth factors and cheiradone. In all cases, the concentration of
cheiradone which caused 50% inhibition (IC50) was determined. The effect of cheiradone on the
binding of growth factors to their receptors was also investigated.
Results: Cheiradone inhibited all stages of VEGF-induced angiogenesis with IC50 values in the range
5.20–7.50 μM but did not inhibit FGF-2 or EGF-induced angiogenesis. It also inhibited VEGF binding
to VEGF receptor-1 and 2 with IC50 values of 2.9 and 0.61 μM respectively.
Conclusion: Cheiradone inhibited VEGF-induced angiogenesis by binding to VEGF receptors -1
and -2 and may be a useful investigative tool to study the specific contribution of VEGF to
angiogenesis and may have therapeutic potential.
Background
Angiogenesis, the growth of new blood vessels from the
existing vasculature is associated with physiological
(wound healing, endometrial cycle and embryonic devel-
opment) and pathological processes (tumour growth,
rheumatoid arthritis, diabetic retinopathy, and brain and
cardiac infarctions) [1,2]. Angiogenesis is mediated by
pro-angiogenic factors including vascular endothelial cell
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angiopoietin, and epidermal growth factor (EGF) [3-6].
VEGF comprises a family of multifunctional cytokines
which include the variants VEGF-A, -B, -C, -D and-E and
placental growth factor (PlGF) [7,8]. VEGF-A is mitogenic
in vitro and angiogenic in vivo [9,10] and its role in angio-
genesis and vasculogenesis has been elucidated [11-13].
At least nine different isoforms of human VEGF-A have
been identified with 121, 145, 148, 162, 165, 183, 189
and 206 amino acid residues [14,8]. Of these, VEGF165 is
most clearly associated with pathological angiogenesis [8]
and exerts its biological action upon binding with two
high affinity receptor tyrosine kinases; VEGFR-1 (flt-1)
and VEGFR-2 (kinase domain receptor; flk-1) [8,15]. The
role of these receptors, especially flk-1 in angiogenesis has
been confirmed through gene knockout studies and flk-1-
/- embryos are unable to form blood islands and to gener-
ate haematopoietic precursors [reviewed in [16]]. VEGFR-
1 has a 50 times higher binding affinity for VEGFR-1 than
VEGFR-2 [17] however, VEGFR-2 has a stronger receptor
tyrosine kinase activity than VEGFR-1 and acts as a major
mitogenic receptor on endothelial cells (ECs) [16,18].
Due to the central role of angiogenesis in tumour growth
and progression it has been a target in cancer therapy. For
example Bevacizumab, a VEGF-A blocking antibody has
been approved for the treatment of metastatic colorectal
cancer [19] and Sunitinib, a VEGF receptor antagonist for
treatment of gastrointestinal stromal tumours and for
advanced renal cell carcinoma [20]. Several other VEGF
inhibitors including the receptor tyrosine kinase inhibi-
tors (RTKIs), Pegaptanib and Sorafenib have been tested
in phase-1 to phase-III clinical trials against VEGF-associ-
ated malignancies [21,22].
Natural compounds from medicinal plants display
diverse pharmacological activities [23] and have advan-
tages over synthetic drugs, such as smoother action, better
tolerance and fewer allergic reactions. Cheiradone, a nat-
urally occurring plant diterpene, was isolated from the
medicinal plant Euphobia chiradenia and in preliminary
screening was shown to be a PLA2 inhibitor, have anti-
inflammatory properties and inhibit wound healing
although the mechanisms of action were not investigated
[24].
In this study we have investigated the effect of cheiradone
on VEGF-induced angiogenesis and show VEGF165 bind-
ing to VEGFR-1 and -2 resultined in inhibition of in vitro
and in vivo angiogenesis.
Results
Cheiradone inhibited VEGF165 binding to VEGFR-1 and -2
Cheiradone was found to specifically inhibit the binding
of VEGF165 to VEGFR-1 and VEGFR-2 in a dose dependent
manner with IC50 values of 2.9 ± 0.31 μM and 0.61 ± 0.14μM respectively (Figure 1; Table 1). No significant inhibi-
tion of FGFR-1 and -2 was observed even at the highest
concentration (328.20 μM) tested (data not included).
Cheiradone inhibited VEGF-induced EC proliferation
Cheiradone was tested to evaluate its effect on cell prolif-
eration in the presence of VEGF, EGF and FGF-2. A con-
centration-dependent inhibition of VEGF-stimulated
BAEC and HDMEC proliferation with IC50 values of 7.4 ±
0.74 and 7.8 ± 1.2 μM respectively (p < 0.005) (Figure 2;
Table 1) was observed. However, no significant inhibition
of FGF-2- and EGF-triggered cell proliferation was
observed (data not included).
Cheiradone inhibited VEGF-induced EC Migration
The effect of cheiradone on the migration of ECs was ana-
lysed using both two- and three-dimensional cell migra-
tion assays. In the two-dimensional assay, a wound-
healing model was used to assess the migratory behaviour
of BAECs and HDMECs (Figure 3). In the VEGF treated
control group, significant wound healing was found 24 h
after the cell monolayer was wounded with a sterile razor
blade (Figure 3Biv; results shown for HDMEC). No signif-
icant inhibition was observed on non-stimulated wound
recovery (Figure 3Biii) However, VEGF- stimulated
Cheiradone inhibits VEGF binding to VEGFR-1 and -2Figu e 1
Cheiradone inhibits VEGF binding to VEGFR-1 and -2. Chei-
radone was incubated with VEGFR-1 and VEGFR-2 in the 
presence of cheiradone (0–3.85 μM) and the binding of 
VEGF165 was measured as described above.
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a dose dependent manner by cheiradone with IC50 values
of 6.5 ± 0.97 and 7.1 ± 0.77 μM respectively (p < 0.05; Fig-
ure 3A and 3Bv). In a three-dimensional cell migration
assay, BAECs and HDMECs treated with VEGF showed 2.8
and 2.5 fold increase in migration to the lower chamber
compared to non-treated cells respectively (Figure 3C).
Cheiradone was found to significantly inhibit (p = 0.001
in each case) VEGF-induced BAEC and HDMEC migration
with IC50 values of 7.5 ± 0.92 and 5.2 ± 0.38 μM respec-
tively.
Cheiradone had no effect on FGF-2 or EGF stimulated
migration in the concentration range used (results not
shown).
Cheiradone inhibited VEGF-induced EC tube formation
To examine the role of cheiradone on EC differentiation
into vascular structures in vitro, tube formation of BAECs
and HDMCs on Matrigel was assessed. When these cells
were stimulated with VEGF, elongated tube-like structures
were formed and the process was inhibited in a dose
dependent manner by cheiradone (Figure 4A). Cheira-
done reduced the width and length of VEGF-induced
HDMEC and BAEC tubes with IC50 values of 6.0 ± 0.38
and 7.7 ± 1.5 μM respectively (p < 0.005; Fig 4Bi–iv,
results are shown for HDMEC). No significant effect of
cheiradone was seen on non-stimulated tube formation
(Figure 4Bii).
Cheiradone inhibited cell invasion
The effect of cheiradone on cell invasion was analysed
using a Transwell Boyden chamber system coated with
reconstituted growth factor-reduced Matrigel. BAECs or
HDMECs were allowed to invade the lower chamber in
the presence and absence of VEGF and cheiradone. A sta-
tistically significant increased in cell invasion was
observed in VEGF treated HDMECs (2.2 fold, p = 0.002)
and BAECs (3.3 fold, p = 0.001) (Figure 5). Cheiradone
showed dose-dependent inhibition of VEGF stimulated
cell invasion of HDMEC and BAEC with IC50 values of 8.3
± 1.0 and 6.3 ± 0.31 μM respectively (p < 0.05).
Cheiradone inhibited angiogenesis in the CAM assay
The above in vitro data suggests that cheiradone inhibits
several steps of angiogenesis in vitro. Therefore, we ana-
lyzed its effect on in vivo angiogenesis using the CAM
assay. After exogenous stimulation of angiogenesis with
VEGF165, significant new blood vessel growth was
observed towards the stimulus after 6 days (Figure 6C, m
= 3, n = 5). There was no significant angiogenic response
to cheiradone alone (Fig 6B, m = 0.5, p = 0.0875, n = 5).
VEGF165-induced blood vessels formation was completely
abolished in the presence of cheiradone (m = 0, n = 5, p =
Cheiradone inhibited cell proliferationFigu e 2
Cheiradone inhibited cell proliferation. Cells were added to a 
6-well plate (seeded cells; BAECs 2 × 104 and HDMECs 3 × 
104) and the effect of cheiradone (0–7.7 μM) on VEGF165 (10 
ng/ml in each case) induced proliferation was determined as 
described above. DMSO alone was added to the control and 
columns 3 and 4 represent cheiradone (7.7 μM) or VEGF 
alone. Values which differ significantly (p < 0.05) from VEGF 
alone are indicated by *.
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Table 1: A summary of the anti-angiogenic properties of cheiradone. IC50 values are The mean of three determinations.
Experiment IC50 value ± SEM (μM)
BAEC HDMEC
VEGF-R1 binding 2.9 ± 0.031
VEGF-R2 binding 0.61 ± 0.14
VEGF induced Proliferation 7.8 ± 1.2 7.4 ± 0.74
Effect on VEGF-induced wound healing 7.1 ± 0.77 6.50 ± .0.97
Effect on VEGF-induced migration 7.5 ± 0.92 5.20 ± 0.38
Effect on VEGF-induced tube formation 7.7 ± 1.5 6.0 ± 0.38
Effect on VEGF-induced invasion 6.3 ± 0.31 8.3 ± 1.0
Toxicity MTT NS NS
Toxicity Caspase-3 NS NS
• NS = Overall inhibition is less than 50% and therefore IC50 values cannot be calculated.Page 3 of 10
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Cheiradone inhibited cell migrationFigu e 3
Cheiradone inhibited cell migration. (A) A cell monolayer was wounded as described and recovery was assessed in the pres-
ence of increasing concentration of cheiradone (0–7.7 μM) and VEGF165 (10 ng/ml in all cases). Controls without VEGF con-
tained either DMSO or cheiradone (7.7 μM). Values significantly different from VEGF alone (p < 0.05) are shown by *. (B) 
Representative photomicrographs show the results for HDMEC: i control, DMSO alone; ii time zero control; iii cheiradone 
7.7 μM; iv treated with VEGF165; 10 ng/ml, v cheiradone + VEGF. (C) The effect cheiradone on VEGF-induced cell migration in 
a three dimensional Boyden chamber assay. Cells were added to the upper chamber and the cheiradone (0–7.7 μM) with and 
without VEGF (10 ng/ml) were added to the lower part. The total number of migrated cells to the lower chamber was counted 
as described above. Controls without VEGF contained either DMSO or cheiradone (5 μM). Values significantly different from 
VEGF alone (p < 0.05) are shown by *.
BAEC 
HDMEC 
* 
* 
* 
Control VEGF (10ng/ml)
N
um
be
r o
f m
ig
ra
te
d 
ce
lls
 
to
 d
en
ud
ed
 a
re
a 
90 
80 
70 
60 
50 
40 
30 
20 
10 
0 
Cheiradone:
(µM)
0 7.7 0 0.77 1.54 7.7
A
B
C BAEC 
HDMEC 
* 
* 
* 
Control VEGF (10ng/ml) Control VEGF (10ng/ml) 
N
um
be
r o
f i
nv
ad
ed
 c
el
ls 
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
0 
Cheiradone: 
(µM) 
0 5 0 1.54 3.85 7.7 0 5 0 1.54 3.85 7.7
* 
* 
* 
v
i iii
iv
ii
BMC Cell Biology 2008, 9:7 http://www.biomedcentral.com/1471-2121/9/70.0001) (Figure 6D). There was no evidence of an inflam-
matory response with cheiradone alone (Fig 6) or in the
control (Figure 6A).
Cytotoxicity study
No significant cytotoxicity was found at the tested concen-
trations of cheiradone (Figure 7A), whereas staurosporine
induced a noticeable cytotoxic effect in the MTT (Figure
7B) and immunofluorescence (Figure 7D) assays.
Discussion
Sesterterpenes are naturally occurring polyisoprene com-
pounds widely distributed in plants and animals. There is
growing interest in these molecules as potential disrupters
of protein-protein interactions [25] since many protein
interfaces are characterised by extended, flat surfaces and
a number of small molecules which interfere with pro-
tein-protein binding have been identified [26]. In addi-
tion, members of the sesterterpene family have moderate
antibacterial activity against Mycobacterium tuberculosis
strain H(37)Rv, inhibit DNA replication [27], are cyto-
toxic against tumour cell lines [28] and have potent
antiplasmodial properties [29].
During angiogenesis, nascent blood vessels grow by
sprouting from the existing vasculature by a cascade of
events including degradation of the basement membrane,
EC migration, proliferation and tube formation [30].
VEGF exerts its angiogenic effect by binding to high affin-
ity receptors on EC. In addition other growth factors, FGF-
2 and EGF and their corresponding receptors are associ-
ated with angiogenesis [31].
(A) Cheiradone inhibits EC differentiation into capillary like structures on MatrigelFigure 4
(A) Cheiradone inhibits EC differentiation into capillary like structures on Matrigel. Cells were treated with either cheiradone 
(control, 0–3.85 μM) or cheiradone (0–3.85 μM) with VEGF (10 ng/ml). Values significantly different from VEGF alone (p < 
0.05) are shown by *. (B) Representative photomicrographs show; i HDMEC, ii HDMEC treated with cheiradone; 7.7 μM, iii 
HDMEC treated with VEGF 10 ng/ml, iv HDMEC treated with VEGF and cheiradone, 7.7 μM. Experiments were performed 
and the number of closed tubes was determined as described above. Results are the mean of three experiments. Incomplete 
tube formation was noted in the presence of cheiradone (ii) but extensive tube formation with VEGF (iii). In the presence of 
cheiradone the effect of VEGF was abolished (iv).
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multiple steps of VEGF-induced angiogenesis in vitro and
in vivo. VEGF is the main regulator of angiogenesis and
elevated levels have been reported in pathological condi-
tions. The binding of VEGF to high affinity tyrosine kinase
receptors such as VEGFR-1 & 2 activates VEGF-dependent
signalling cascades which initiate the early events of ang-
iogenesis (cell proliferation and migration from the
lumen of existing vessels). Our in vitro inhibition data
showed that cheiradone appeared to inhibit EC prolifera-
tion and migration with IC50 values in the range 5.2–7.8μM. In the later stages of angiogenesis, ECs differentiate
into tubular like structures that eventually form the lumen
of the new vessel. The in vitro Matrigel tube formation
assay showed that cheiradone inhibited VEGF-induced
tube-like structures at low concentrations. We also dem-
onstrated that cheiradone completely inhibited angiogen-
esis in vivo using the CAM assay. Therefore, cheiradone
appears an effective antagonist of angiogenesis. Cheira-
done was equally effective at inhibiting angiogenesis in
both large vessel-derived (BAEC) and small vessel-derived
cells (HDMEC; the in vivo target of angiogenic modula-
tors).
Binding studies with VEGFR-1 and -2 showed significant
inhibition of VEGF binding in the presence of cheiradone,
with stronger inhibition of VEGFR-2. When cells were pre-
incubated with cheiradone, and the cheiradone removed
prior to addition of VEGF a significant inhibition of cell
proliferation was still observed, indicating that cheira-
done was not interacting directly with VEGF. Instead chei-
radone competed with VEGF for binding to a VEGF
Cheiradone inhibits in vivo angiogenesis in the CAM assayFigu e 6
Cheiradone inhibits in vivo angiogenesis in the CAM assay. 
(A) control, methylcellulose alone showed no evidence of 
angiogenesis or inflammation (B) cheiradone (10 μg) failed to 
induce blood vessel formation (C) VEGF, a network of new 
blood vessels was established (see arrow) at the point of 
application. (D) cheiradone (10 μg) + VEGF inhibited vessel 
formation. There was no evidence of an inflammatory 
response in any preparation. Representative photomicro-
graphs are shown. Magnification ×50.
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Cheiradone inhibits cell invasionFigu e 5
Cheiradone inhibits cell invasion. The effect of cheiradone on 
BAEC, and HDMEC cell invasion was studied using the chem-
oinvasion assay. Cells (1.7 × 104) were added to the Matrigel 
coated upper Boyden chamber and cheiradone (0–7.7 μM) 
(control) or cheiradone with VEGF (10 ng/ml) was added to 
the lower chamber. Cell invasion was measured after 24 h 
and assessed as described above. Values significantly different 
(p < 0.05) from VEGF alone are shown by *.
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BMC Cell Biology 2008, 9:7 http://www.biomedcentral.com/1471-2121/9/7receptor. Both VEGFR-1 and -2 contain extracellular, jux-
tamembrane and tyrosine kinase domains. We have no
evidence which domain cheiradone binds to and are cur-
rently investigating the tyrosine kinase activity of the
VEGF receptors in the presence of the inhibitor. An addi-
tional mechanism by which cheiradone can affect VEGF-
induced angiogenesis is by regulating the expression levels
of VEGFR-1 and/or VEGFR-2. We are currently investigat-
ing the interaction of cheiradone with the receptors on
endothelial cells.
Semino et al., [32] have developed an in vivo model of
angiogenesis in the presence of interstitial flow. They pro-
pose a two step model of angiogenesis requiring initial
activation by VEGF and subsequent maturation of the
new blood vessel on exposure to EGF. Cheiradone would
be an ideal molecule to test this model since it has no
activity against EGF. In vivo, VEGFR-1 is constitutively
expressed in the blood vascular system while VEGFR-2 is
down regulated but is over expressed in angiogeneic
endothelial cells and after hypoxia [33]. We have shown
that cheiradone is more active against VEGFR-2 and may
therefore be a more specific molecule for targeting ang-
iogenic blood vessels in diseases such as cancer.
In addition, cytotoxicity studies showed that cheiradone
had no adverse effects at concentrations greater than those
used in the present study.
The advantage of cheiradone over existing VEGF inhibi-
tors is that it does not remove VEGF from the system and
VEGF activity may be modulated by varying the concen-
tration of cheiradone.
Conclusion
We have demonstrated that cheiradone, a naturally occur-
ring sesterterpene inhibits VEGF-induced angiogenesis by
competing with VEGF for VEGFR-1 and -2. There was no
activity against FGF-2 or EGF. Further study of the struc-
tural relationships of cheiradone and its activity may pro-
vide a basis for designing VEGF receptor antagonist with
enhanced inhibitory potential and improved specificity.
Methods
Test compound
Cheiradone (Fig 8; RMM 613) was extracted and purified
from Euphorbia cheiradenia Boiss. Full chemical character-
isation and purification is detailed elsewhere [24].
Materials
Matrigel (Becton Dickinson, UK), FGF-2, goat anti-active
caspase-3 antibody (R&D System), VEGF165 (Apollo
Cytokine Research, Cambridge, UK), EGF, VEGFR-1 and -
2 and FGFR-1 and -2, anti-FGF-2 and anti-VEGF antibod-
ies (Santa Cruz Biotechnology, Heidelberg, GDR), ABTS
peroxidase substrate kit (Vector, UK), Transwell chamber
system, culture plates and flasks (SLS, UK), anti-goat Alexa
flour 488 conjugated green fluorescence dye and other
chemical of commercial grade were purchased from
Sigma (Poole, UK).
Cell Culture
Human dermal microvascular endothelial cells
(HDMECs) and the appropriate medium were purchased
from TCS Cellworks (Buckingham, UK) and were cultured
and maintained according to the supplier's instructions.
Bovine aortic endothelial cells (BAECs) were from an
established large vessel primary cell culture obtained and
characterised as described previously [34]. They were rou-
Investigation of the cytotoxic effect of cheiradone on BAEC and HDMEC viabilityFigure 7
Investigation of the cytotoxic effect of cheiradone on BAEC 
and HDMEC viability. The cytotoxic effect of cheiradone was 
determined using (A) MTT assay and (B) Active-caspase-3 
apoptosis assay. Cells were incubated with cheiradone and 
staurosporine (1.4 μM) for 24 h. Values significantly different 
from the control (DMSO) are shown by *. Immunofluores-
cence photomicrographs for HMDEC were taken as 
described above and show. (C) control, DMSO (D stau-
rosporine, the arrow indicates a positively stained apoptotic 
cell and (E) cheiradone.
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BMC Cell Biology 2008, 9:7 http://www.biomedcentral.com/1471-2121/9/7tinely cultured in Dulbecco's modified Eagles medium
(DMEM) containing varying concentrations of foetal calf
serum (FCS). All cells were used between passages six to
nine.
Cell proliferation assay
Cells were seeded in triplicate at a concentration of 2.5 ×
104/ml, in 2 ml of complete medium in 6-well plates.
After attachment (24 h), medium was replaced with
serum poor medium (SPM), containing 2.5% foetal calf
serum in which the cells grew at a significantly reduced
rate. Growth factors FGF-2 and EGF (25 ng/ml), and
VEGF165 (10 ng/ml) with and without the test compound
at different concentrations was added and cells incubated
for a further 72 h. Control wells were treated with 5 μl
DMSO. Concentration ranges of test compounds and pre-
incubation times were based on pilot studies. MTT and
immunofluorescence studies using active caspase-3 as a
measure of apoptosis confirmed that test compounds
were not cytotoxic at the concentrations used (see below).
After 72 h, cells were washed in PBS, detached in 0.05%w/
v trypsin in PBS, and counted on a Coulter counter (Coul-
ter Electronics, Hialeah, FL) set to a threshold of 30 μm.
Experiments were performed at least twice in triplicate
wells and significance was determined by the Student t
test. A representative example is shown.
Cell migration assay
Cell migration was examined in vitro using a Transwell
chamber system with 8.0 μm pore polycarbonate filter
inserts (TSL, UK). The Transwell insert was coated over-
night with 0.1%w/v gelatine, and air-dried. Cells (1 × 105)
were placed in the upper part of the filter and test com-
pounds at different concentrations with and without
growth factors were added to the lower part in SPM. Cells
were incubated at 37°C for 16 h. After fixation (4% para-
formaldehyde), and staining (Geimsa), cell migration in
duplicate wells was determined by counting cell numbers
on the lower surface. Experiments were performed at least
twice and a representative example is shown. Significance
was determined by the Student t test.
Wound healing assay
Cells (6 × 104/ml) were added to a Thrermanox cover slip
in a 24-well plate in complete medium and incubated for
24–48 h. When confluent, the medium was replaced with
DMEM containing 0.1% FCS and incubated for a further
48 h. Cover slips were washed (PBS, ×3), wounded with a
sterile razor to produce a straight edged cut and washed in
PBS to remove dislodged cells. Cover slips were added to
a fresh 24-well plate in 0.1% FCS and incubated with
VEGF165 or the other growth factors and a range of concen-
trations of test compound for 24 h. Under these condi-
tions there was negligible proliferation but measurable
migration. Slides were fixed in ethanol (100%), stained
with methylene blue and photographed. For each slide,
10 fields of view (2 mm × 1.45 mm) were counted at ran-
dom. Each experiment was performed at least twice and
significance was determined by the Student t test.
Cell differentiation assays in Matrigel
Cells (1.0 × 106/ml) were mixed with an equal volume of
Matrigel at 4°C. Aliquots (45 μl) were added to the wells
of a 48-well plate and allowed to polymerise (1 h) when
500 μl of microvascular endothelial cell medium contain-
ing VEGF165 or the other growth factors, with or without
the test compound was added. The cells were incubated
for 24 h at 37°C then fixed in 4% paraformaldehyde (5
min), washed in cold ethanol and air dried. Cells were
stained with Geimsa (30 sec), air dried and photo-
graphed. Ten random fields were selected and the number
of closed tubes counted.
All experiments were performed in triplicate and repeated
at least twice and significance was determined by the Stu-
dent t test.
Chemoinvasion assay
A Transwell cell culture chamber with 6.5-mm-diameter
polycarbonate filters (8-μm pore size) were coated with
30 μg/ml Matrigel. Cells (1 × 105) were added to the upper
chamber suspended in an appropriate medium. The
The structure of cheiradoneFigure 8
The structure of cheiradone.
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pound was added to the lower chamber in the presence
and absence of VEGF165 or the other growth factors. After
24 h incubation at 37°C, the medium from the lower
chamber was removed, cell fixed (4% paraformaldehyde)
and stained. The number of cells invaded to the lower
chamber through the Matrigel was counted under phase-
contrast microscopy. Each invasion experiment was per-
formed in triplicate and repeated at least twice. Statistical
significance was determined using the Student t test.
Binding assay
Competition between growth factors, their cell surface
receptors and test compounds was assessed as described
previously [35]. A 96-well plate was coated overnight with
growth factors (2 μg/ml of VEGF165 or FGF-2) and blocked
with 1% BSA in PBS containing 0.05% Tween-20. The test
compound was separately pre-mixed with soluble recep-
tors VEGFR-1, VEGFR-2, FGFR-1 or FGFR-2 (2 μg/ml in
each case) for 2 h and added to the plate and incubated for
a further 2 h. The plate was washed (×3 with PBS-Tween-
20) and incubated with anti-VEGF or anti-FGF-2 antibody
(1:500 in PBS-Tween-20) for 45 min, washed and incu-
bated with horseradish peroxidase conjugated goat anti-
IgG (Santa Cruz, 1:1000) for a further 45 min. After wash-
ing (×3), ABTS peroxidase substrate (Vector, UK) was
added and the absorbance read at 405 nm. IC50 values
were calculated from the data using the EZ-Fit enzyme
kinetic software (Perella Scientific Inc., Amherst, USA).
Chick chorioallantoic assay
The angiogenic activity of cheiradone was determined
using the semi-quantitative chick chorioallantoic assay
(CAM) as described previously [36]. To expose the CAM a
window was created in the shells of 4 day-old chicken
eggs. On day 8, a 2 mm3 methycellulose pellet (5 μl of 1%
sterile methylcellulose; 400 centipoise, Sigma UK) con-
taining no additions (control), the test compound (10 μg)
with and without VEGF (100 ng) were applied to the
membrane. The resultant angiogenesis scored on day 14
as 0- negative; 0.5- change in vessel architecture; 1- partial
spokewheel (1/3 of circumference exhibits directional
angiogenesis); 2- spokewheel; 3 or greater-strong and fully
spokewheel. This approach enabled calculation of an
accumulated response in each group. To photograph the
membrane, 2 cm3 of a 50% emulsion of aqueous paraffin
oil containing 2% Tween-80 was injected at the site of
application and photographed using a Leitz dissecting
microscope. Each experiment was performed five times
and statistical significance was determined by the Mann-
Whitney U test and the data is expressed as a median value
(m).
Toxicity Assays
Cheiradone toxicity was determined using MTT and active
caspase-3 assays. BAECs or HDMECs (7.5 × 103) were
seeded in a 96 well plate and incubated for 4 h to allow
cell adhesion. Cheiradone or staurosporine, an inducer of
active caspase-3 and therefore, of apoptosis (1 μM) was
added to the wells. Control cells were treated with PBS
and the plate was incubated at room temperature for 72
hours. MTT reagent (10 μl) was added followed by incu-
bation at room temperature for 2–4 h. When a purple pre-
cipitate was visible, detergent reagent (100 μl) was added
to the plates and incubated at room temperature for 2 h in
the dark. Absorbance was measured at 570 nm using a
microplate reader.
In the apoptosis assay, HDMECs or BAEC (4 × 104/ml) in
complete medium were added to the chambers slide and
allowed to adhere for 24 h. Cheiradone (8.2 μM) or stau-
rosporine (1 μM) were added to all wells except control
(PBS) and incubated for 24 hours. Wells treated with stau-
rosporine were immediately washed (PBS) and fixed (4%
paraformaldehyde) when cell morphology became round
(2–4 h). After washing and fixing, cells were permeablized
(0.1% Triton X-100; 10 min), washed (×5 ~ 5 min each),
air dried and blocked with 1% BSA in 1:50 TBS Tween for
1 h at room temperature. Cells were incubated with goat
anti-active caspase-3 (R&D system, UK; 1% BSA in TBS
Tween) for 1 h. The plates were incubated with anti-goat
Alexa-Flour 488 conjugated green fluorescent dye for 1.5
h at room temperature. Ten random homogeneous fields
were viewed, and photographed.
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